Latest Partnerships News

Alicanto Minerals Limited has announced a 12-for-1 consolidation of its securities, including ordinary shares, performance rights, and options, effective from late January 2026. This move will significantly reduce the number of securities on issue and adjust option exercise prices accordingly.

Peako Limited has intensified its exploration efforts in the East Kimberley region, targeting multiple mineral commodities while implementing prudent cash flow measures including director remuneration deferrals.

Osteopore Limited has inked an exclusive collaboration with Majeton to commercialise its cutting-edge 3D-printed bioresorbable implants across China, Hong Kong, and Macau, unlocking significant growth potential in the region.

NOVONIX has delayed the start of mass production of battery-grade synthetic graphite anode material for Panasonic Energy to the second half of 2027, while maintaining its 2026 target for industrial-grade graphite production.

Navigator Global Investments reported steady ownership-adjusted assets under management of USD29 billion for the December 2025 quarter, buoyed by strong hedge fund performance and resilient private markets growth despite the Bardin Hill sale.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Vitasora Health has completed an A$11 million capital raise, including a cornerstone investment, bolstering its balance sheet to support ambitious growth in the US healthcare market. The company targets cash flow breakeven by the end of FY2026 amid expanding patient programs and new partnerships.

Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.

Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

Oneview Healthcare reported a stronger cash position in Q4 2025 alongside a key expansion of its US footprint through a new partnership with a Top 10 health system. The company’s strategic moves set the stage for growth in 2026.

Findi Limited has landed a significant pre-IPO investment from Nova Global Opportunities Fund PCC, setting the stage for its Indian subsidiary’s planned listing on the Bombay Stock Exchange by FY27. This deal supports a Findi share price target between $5.58 and $6.69.